Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：214頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2014’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2014’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Plaque Psoriasis (Psoriasis Vulgaris) Overview 9
Therapeutics Development 10
Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Overview 10
Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis 11
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies 12
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies 21
Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development 25
Alcon, Inc. 25
Johnson & Johnson 26
Kyowa Hakko Kirin Co., Ltd. 27
Valeant Pharmaceuticals International, Inc. 28
Amgen Inc. 29
GlaxoSmithKline plc 30
Celltrion, Inc. 31
Biocon Limited 32
LEO Pharma A/S 33
Pfizer Inc. 34
Celgene Corporation 35
Idera Pharmaceuticals, Inc. 36
Almirall, S.A. 37
Protalix BioTherapeutics, Inc. 38
Biotie Therapies Corp. 39
R-Tech Ueno, Ltd. 40
Viropro Inc. 41
Anacor Pharmaceuticals, Inc. 42
Circassia Ltd 43
Novaliq GmbH 44
Vascular Biogenics Ltd. 45
ISDIN 46
Promius Pharma, LLC 47
Avesthagen Limited 48
Maruho Co., Ltd. 49
Shanghai Celgen Bio-Pharmaceutical Co., Ltd. 50
CalciMedica, Inc. 51
Biosidus S.A. 52
XBiotech USA, Inc. 53
Genor BioPharma Co., Ltd. 54
Aprogen, Inc. 55
Lipidor AB 56
Forward Pharma A/S 57
Delenex Therapeutics AG 58
Creabilis SA 59
bioXPRESS Therapeutics SA 60
Dermira Inc. 61
Cormorant Pharmaceuticals AB 62
PanPharmaceuticals USA, Inc. 63
Epirus Biopharmaceuticals, Inc. 64
AlphaMab Co., Ltd 65
Pharmapraxis 66
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment 67
Assessment by Monotherapy Products 67
Assessment by Combination Products 68
Assessment by Target 69
Assessment by Mechanism of Action 73
Assessment by Route of Administration 77
Assessment by Molecule Type 80
Drug Profiles 83
secukinumab - Drug Profile 83
infliximab biosimilar - Drug Profile 86
brodalumab - Drug Profile 87
tofacitinib - Drug Profile 89
apremilast - Drug Profile 93
(calcipotriol + betamethasone dipropionate) - Drug Profile 95
pefcalcitol - Drug Profile 96
dimethyl fumarate - Drug Profile 97
infliximab biosimilar - Drug Profile 98
tacrolimus Microemulsion - Drug Profile 99
M-801801 - Drug Profile 100
adalimumab biosimilar - Drug Profile 101
DFD-01 - Drug Profile 102
ASKP-1240 - Drug Profile 103
IMO-3100 - Drug Profile 104
CT-327 - Drug Profile 106
LEO-90110 - Drug Profile 108
VB-201 - Drug Profile 109
LAS-41004 - Drug Profile 111
AN-2728 - Drug Profile 112
guselkumab - Drug Profile 114
GSK-2245840 - Drug Profile 116
DRM-02 - Drug Profile 118
pefcalcitol - Drug Profile 119
DLX-105 - Drug Profile 120
RA-18-C-3 - Drug Profile 121
IDP-118 - Drug Profile 123
IMO-8400 - Drug Profile 124
MOL-4239 - Drug Profile 126
AM-001 - Drug Profile 127
HuMax-IL8 - Drug Profile 128
calcipotriene - Drug Profile 129
BTT-1023 - Drug Profile 130
guselkumab - Drug Profile 131
cyclosporine - Drug Profile 133
CIR-001 - Drug Profile 134
CM-2489 - Drug Profile 135
SHP-141 - Drug Profile 137
infliximab biosimilar - Drug Profile 138
LEO-35299 - Drug Profile 139
infliximab biosimilar - Drug Profile 140
adalimumab biosimilar - Drug Profile 141
adalimumab biosimilar - Drug Profile 142
RTU-1096 - Drug Profile 143
etanercept biosimilar - Drug Profile 144
adalimumab biosimilar - Drug Profile 145
etanercept biosimilar - Drug Profile 146
etanercept biosimilar - Drug Profile 147
ustekinumab biosimilar - Drug Profile 148
etanercept biosimilar - Drug Profile 149
adalimumab biosimilar - Drug Profile 150
adalimumab biosimilar - Drug Profile 151
etanercept biosimilar - Drug Profile 152
adalimumab biosimilar - Drug Profile 153
infliximab biosimilar - Drug Profile 154
etanercept biosimilar - Drug Profile 155
adalimumab biosimilar - Drug Profile 156
adalimumab biosimilar - Drug Profile 157
infliximab biosmiliar - Drug Profile 158
etanercept biosimilar - Drug Profile 159
etanercept biosimilar - Drug Profile 160
Plaque Psoriasis (Psoriasis Vulgaris) - Recent Pipeline Updates 161
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects 197
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products 198
Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones 199
Featured News & Press Releases 199
Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 210
Disclaimer 210
List of Tables
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2014 14
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Development by Companies, H1 2014 (Contd..3) 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Development, H1 2014 23
Comparative Analysis by Unknown Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Development by Companies, H1 2014 (Contd..3) 28
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Alcon, Inc., H1 2014 29
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H1 2014 30
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 31
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2014 32
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H1 2014 33
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline plc, H1 2014 34
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celltrion, Inc., H1 2014 35
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H1 2014 36
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H1 2014 37
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H1 2014 38
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celgene Corporation, H1 2014 39
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 40
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H1 2014 41
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H1 2014 42
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biotie Therapies Corp., H1 2014 43
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by R-Tech Ueno, Ltd., H1 2014 44
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Viropro Inc., H1 2014 45
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 46
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Circassia Ltd, H1 2014 47
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novaliq GmbH, H1 2014 48
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Vascular Biogenics Ltd., H1 2014 49
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by ISDIN, H1 2014 50
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H1 2014 51
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avesthagen Limited, H1 2014 52
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H1 2014 53
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H1 2014 54
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by CalciMedica, Inc., H1 2014 55
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biosidus S.A., H1 2014 56
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech USA, Inc., H1 2014 57
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co., Ltd., H1 2014 58
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Aprogen, Inc., H1 2014 59
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H1 2014 60
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H1 2014 61
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Delenex Therapeutics AG, H1 2014 62
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Creabilis SA, H1 2014 63
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by bioXPRESS Therapeutics SA, H1 2014 64
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Dermira Inc., H1 2014 65
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cormorant Pharmaceuticals AB, H1 2014 66
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by PanPharmaceuticals USA, Inc., H1 2014 67
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2014 68
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AlphaMab Co., Ltd, H1 2014 69
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pharmapraxis, H1 2014 70
Assessment by Monotherapy Products, H1 2014 71
Assessment by Combination Products, H1 2014 72
Number of Products by Stage and Target, H1 2014 75
Number of Products by Stage and Mechanism of Action, H1 2014 79
Number of Products by Stage and Route of Administration, H1 2014 83
Number of Products by Stage and Molecule Type, H1 2014 86
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Recent Pipeline Updates, H1 2014 165
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H1 2014 201
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H1 2014 202
List of Figures
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2014 14
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Products, H1 2014 23
Assessment by Monotherapy Products, H1 2014 71
Number of Products by Top 10 Target, H1 2014 73
Number of Products by Stage and Top 10 Target, H1 2014 74
Number of Products by Top 10 Mechanism of Action, H1 2014 77
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 78
Number of Products by Top 10 Route of Administration, H1 2014 81
Number of Products by Stage and Top 10 Route of Administration, H1 2014 82
Number of Products by Top 10 Molecule Type, H1 2014 84
Number of Products by Stage and Top 10 Molecule Type, H1 2014 85
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Plaque Psoriasis (Psoriasis Vulgaris) Overview 9
Therapeutics Development 10
Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Overview 10
Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis 11
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies 12
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies 21
Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development 25
Alcon, Inc. 25
Johnson & Johnson 26
Kyowa Hakko Kirin Co., Ltd. 27
Valeant Pharmaceuticals International, Inc. 28
Amgen Inc. 29
GlaxoSmithKline plc 30
Celltrion, Inc. 31
Biocon Limited 32
LEO Pharma A/S 33
Pfizer Inc. 34
Celgene Corporation 35
Idera Pharmaceuticals, Inc. 36
Almirall, S.A. 37
Protalix BioTherapeutics, Inc. 38
Biotie Therapies Corp. 39
R-Tech Ueno, Ltd. 40
Viropro Inc. 41
Anacor Pharmaceuticals, Inc. 42
Circassia Ltd 43
Novaliq GmbH 44
Vascular Biogenics Ltd. 45
ISDIN 46
Promius Pharma, LLC 47
Avesthagen Limited 48
Maruho Co., Ltd. 49
Shanghai Celgen Bio-Pharmaceutical Co., Ltd. 50
CalciMedica, Inc. 51
Biosidus S.A. 52
XBiotech USA, Inc. 53
Genor BioPharma Co., Ltd. 54
Aprogen, Inc. 55
Lipidor AB 56
Forward Pharma A/S 57
Delenex Therapeutics AG 58
Creabilis SA 59
bioXPRESS Therapeutics SA 60
Dermira Inc. 61
Cormorant Pharmaceuticals AB 62
PanPharmaceuticals USA, Inc. 63
Epirus Biopharmaceuticals, Inc. 64
AlphaMab Co., Ltd 65
Pharmapraxis 66
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment 67
Assessment by Monotherapy Products 67
Assessment by Combination Products 68
Assessment by Target 69
Assessment by Mechanism of Action 73
Assessment by Route of Administration 77
Assessment by Molecule Type 80
Drug Profiles 83
secukinumab - Drug Profile 83
infliximab biosimilar - Drug Profile 86
brodalumab - Drug Profile 87
tofacitinib - Drug Profile 89
apremilast - Drug Profile 93
(calcipotriol + betamethasone dipropionate) - Drug Profile 95
pefcalcitol - Drug Profile 96
dimethyl fumarate - Drug Profile 97
infliximab biosimilar - Drug Profile 98
tacrolimus Microemulsion - Drug Profile 99
M-801801 - Drug Profile 100
adalimumab biosimilar - Drug Profile 101
DFD-01 - Drug Profile 102
ASKP-1240 - Drug Profile 103
IMO-3100 - Drug Profile 104
CT-327 - Drug Profile 106
LEO-90110 - Drug Profile 108
VB-201 - Drug Profile 109
LAS-41004 - Drug Profile 111
AN-2728 - Drug Profile 112
guselkumab - Drug Profile 114
GSK-2245840 - Drug Profile 116
DRM-02 - Drug Profile 118
pefcalcitol - Drug Profile 119
DLX-105 - Drug Profile 120
RA-18-C-3 - Drug Profile 121
IDP-118 - Drug Profile 123
IMO-8400 - Drug Profile 124
MOL-4239 - Drug Profile 126
AM-001 - Drug Profile 127
HuMax-IL8 - Drug Profile 128
calcipotriene - Drug Profile 129
BTT-1023 - Drug Profile 130
guselkumab - Drug Profile 131
cyclosporine - Drug Profile 133
CIR-001 - Drug Profile 134
CM-2489 - Drug Profile 135
SHP-141 - Drug Profile 137
infliximab biosimilar - Drug Profile 138
LEO-35299 - Drug Profile 139
infliximab biosimilar - Drug Profile 140
adalimumab biosimilar - Drug Profile 141
adalimumab biosimilar - Drug Profile 142
RTU-1096 - Drug Profile 143
etanercept biosimilar - Drug Profile 144
adalimumab biosimilar - Drug Profile 145
etanercept biosimilar - Drug Profile 146
etanercept biosimilar - Drug Profile 147
ustekinumab biosimilar - Drug Profile 148
etanercept biosimilar - Drug Profile 149
adalimumab biosimilar - Drug Profile 150
adalimumab biosimilar - Drug Profile 151
etanercept biosimilar - Drug Profile 152
adalimumab biosimilar - Drug Profile 153
infliximab biosimilar - Drug Profile 154
etanercept biosimilar - Drug Profile 155
adalimumab biosimilar - Drug Profile 156
adalimumab biosimilar - Drug Profile 157
infliximab biosmiliar - Drug Profile 158
etanercept biosimilar - Drug Profile 159
etanercept biosimilar - Drug Profile 160
Plaque Psoriasis (Psoriasis Vulgaris) - Recent Pipeline Updates 161
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects 197
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products 198
Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones 199
Featured News & Press Releases 199
Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 210
Disclaimer 210
List of Tables
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2014 14
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Development by Companies, H1 2014 (Contd..3) 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Development, H1 2014 23
Comparative Analysis by Unknown Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Development by Companies, H1 2014 (Contd..3) 28
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Alcon, Inc., H1 2014 29
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H1 2014 30
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 31
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2014 32
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H1 2014 33
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline plc, H1 2014 34
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celltrion, Inc., H1 2014 35
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H1 2014 36
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H1 2014 37
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H1 2014 38
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celgene Corporation, H1 2014 39
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 40
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H1 2014 41
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H1 2014 42
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biotie Therapies Corp., H1 2014 43
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by R-Tech Ueno, Ltd., H1 2014 44
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Viropro Inc., H1 2014 45
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 46
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Circassia Ltd, H1 2014 47
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novaliq GmbH, H1 2014 48
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Vascular Biogenics Ltd., H1 2014 49
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by ISDIN, H1 2014 50
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H1 2014 51
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avesthagen Limited, H1 2014 52
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H1 2014 53
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H1 2014 54
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by CalciMedica, Inc., H1 2014 55
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biosidus S.A., H1 2014 56
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech USA, Inc., H1 2014 57
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co., Ltd., H1 2014 58
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Aprogen, Inc., H1 2014 59
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H1 2014 60
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H1 2014 61
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Delenex Therapeutics AG, H1 2014 62
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Creabilis SA, H1 2014 63
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by bioXPRESS Therapeutics SA, H1 2014 64
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Dermira Inc., H1 2014 65
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cormorant Pharmaceuticals AB, H1 2014 66
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by PanPharmaceuticals USA, Inc., H1 2014 67
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2014 68
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AlphaMab Co., Ltd, H1 2014 69
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pharmapraxis, H1 2014 70
Assessment by Monotherapy Products, H1 2014 71
Assessment by Combination Products, H1 2014 72
Number of Products by Stage and Target, H1 2014 75
Number of Products by Stage and Mechanism of Action, H1 2014 79
Number of Products by Stage and Route of Administration, H1 2014 83
Number of Products by Stage and Molecule Type, H1 2014 86
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Recent Pipeline Updates, H1 2014 165
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H1 2014 201
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H1 2014 202
List of Figures
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2014 14
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Products, H1 2014 23
Assessment by Monotherapy Products, H1 2014 71
Number of Products by Top 10 Target, H1 2014 73
Number of Products by Stage and Top 10 Target, H1 2014 74
Number of Products by Top 10 Mechanism of Action, H1 2014 77
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 78
Number of Products by Top 10 Route of Administration, H1 2014 81
Number of Products by Stage and Top 10 Route of Administration, H1 2014 82
Number of Products by Top 10 Molecule Type, H1 2014 84
Number of Products by Stage and Top 10 Molecule Type, H1 2014 85
